Idorsia Ltd (SWX:IDIA)
3.782
+0.082 (2.22%)
Apr 22, 2026, 5:30 PM CET
Idorsia Revenue
In the year 2025, Idorsia had annual revenue of 220.58M CHF with 96.06% growth. Idorsia had revenue of 47.97M in the quarter ending December 31, 2025, a decrease of -19.91%.
Revenue
220.58M
Revenue Growth
+96.06%
P/S Ratio
4.31
Revenue / Employee
339.36K
Employees
650
Market Cap
951.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 232.38M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Xlife Sciences AG | 839.38K |
| Molecular Partners AG | 681.00K |
| Addex Therapeutics | 158.54K |
Idorsia News
- 12 days ago - Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders - GlobeNewsWire
- 13 days ago - Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development - GlobeNewsWire
- 23 days ago - Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up - Nasdaq
- 4 weeks ago - Idorsia announces the nomination of three candidates for election to the Board of Directors - GlobeNewsWire
- 5 weeks ago - Idorsia announces management change - GlobeNewsWire
- 6 weeks ago - Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink - GlobeNewsWire
- 7 weeks ago - Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 - GlobeNewsWire
- 2 months ago - Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call - GlobeNewsWire